Corvus Pharmaceuticals Inc. (CRVS)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 5.34 |
Market Cap | 344.10M |
Revenue (ttm) | 236.99K |
Net Income (ttm) | -54.75M |
EPS (ttm) | -0.99 |
PE Ratio (ttm) | -5.41 |
Forward PE | -18.1 |
Analyst | Buy |
Ask | 5.37 |
Volume | 422,322 |
Avg. Volume (20D) | 1,159,655 |
Open | 5.27 |
Previous Close | 5.22 |
Day's Range | 5.26 - 5.59 |
52-Week Range | 1.30 - 10.00 |
Beta | 1.04 |
About CRVS
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat pa...
Analyst Forecast
According to 5 analyst ratings, the average rating for CRVS stock is "Buy." The 12-month stock price forecast is $12.5, which is an increase of 133.43% from the latest price.
Why Price Moved
News
2 months ago · seekingalpha.com
Corvus Pharmaceuticals, Inc. (CRVS) Q3 2024 Earnings Call TranscriptCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Zack Kubow - Real Chemistry, IR Leiv Lea - Chief Financial Officer Richar...